Inventor
Ralf Hosse
Inventor
Cham, CH
Overview
Patents· 33 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes28%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
C07KPeptides28%
C12NMicroorganisms or enzymes9%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
A61NElectrotherapy2%
C12YEnzymes1%
PatentTitleYear
11,130,822Immunoconjugates202111,111,312Mutant interleukin-2 polypeptides202111,098,099Interleukin-2 fusion proteins and uses thereof202110,851,171Method for the selection of antibodies against BCMA202010,781,258Bispecific T cell activating antigen binding molecules202010,781,257Bispecific T cell activating antigen binding molecules202010,745,470Modified anti-tenascin antibodies and methods of use202010,584,178Bispecific HER2 antibodies and methods of use202010,577,429Anti-FAP antibodies and methods of use202010,562,949Interleukin-2 fusion proteins and uses thereof202010,526,413Bispecific antibodies specific for OX40202010,323,098Mutant interleukin-2 polypeptides201910,316,104Immunoconjugates201910,253,110Anti-FAP antibodies and methods of use201910,253,104Bispecific antibodies against CD3[?] and BCMA201910,202,464Immunoconjugates201910,184,009Mutant interleukin-2 polypeptides201910,155,815Bispecific T cell activating antigen binding molecules201810,077,315Bispecific antibodies against CD3 and BCMA201810,040,843Interleukin-10 fusion proteins and uses thereof20189,963,513Method for the selection of antibodies against BCMA20189,926,379'Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5'20189,650,442'Bispecific anti-EGFR/anti IGF-1R antibodies'20179,447,159'Immunoconjugates'20169,346,872'Interleukin-10 fusion proteins'20169,266,938'Mutant interleukin-2 polypeptides'20169,206,260'Anti-CEA antibodies'20159,156,913'Anti-tenascin-C A2 antibodies and methods of use'20159,068,008'Antibodies to carcinoembryonic antigen (CEA), methods of making same, and uses thereof'20159,011,847'Anti-FAP antibodies and methods of use'20158,945,571'Targeted immunoconjugates'20158,642,742'Anti-CEA antibodies'20147,691,987'Use of a novel eimeria gene and corresponding protein'2010Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2010Based in Düsseldorf, DE· patent location history
2014–2021Patents assigned to ROCHE GLYCART AG (23)· patent assignee history
2014–2016Patents assigned to HOSSE RALF (5)· patent assignee history
2014–2016Patents assigned to MOESSNER EKKEHARD (5)· patent assignee history
2014–2016Patents assigned to HOFER THOMAS U (4)· patent assignee history
2014–2021Based in Cham, CH· patent location history
2015Based in Bonstetten, CH· patent location history
2020–2021Patents assigned to HOFFMANN LA ROCHE (4)· patent assignee history
2020Based in Schlieren, CH· patent location history
2020Based in Mettmenstetten, CH· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ROCHE GLYCART AG | 23 | 2014–2021 |
| HOSSE RALFself | 5 | 2014–2016 |
| MOESSNER EKKEHARD | 5 | 2014–2016 |
| HOFER THOMAS U | 4 | 2014–2016 |
| HOFFMANN LA ROCHE | 4 | 2020–2021 |
Locations
| Location | Patents | Span |
|---|---|---|
| Cham, CH | 27 | 2014–2021 |
| Schlieren, CH | 2 | 2020 |
| Bonstetten, CH | 2 | 2015 |
| Mettmenstetten, CH | 1 | 2020 |
| Düsseldorf, DE | 1 | 2010 |